Overview

Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Status:
Not yet recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.

Phase:

Phase 2

Details

Lead Sponsor:

Northside Hospital, Inc.

Treatments:

Blinatumomab
Methotrexate